A 308-patient pivotal trial of personalized transcranial magnetic stimulation for chronic tinnitus reported clinically meaningful symptom reduction at 12 weeks compared with sham. The protocol uses MEG-guided localization of auditory cortex hyperactivity in each patient and delivers 1Hz inhibitory stimulation to the identified site.
Tinnitus Functional Index scores dropped by an average of 16.1 points in the active arm versus 7.4 in sham — a difference that meets the threshold for clinical relevance. Approximately one-third of patients reported their tinnitus was "much improved" or "very much improved" at 12 weeks.
The manufacturer indicated the data will support an FDA submission expected in mid-2026. If cleared, it would be the first FDA-cleared device specifically indicated for tinnitus, a condition affecting roughly 25 million U.S. adults with limited evidence-based treatment options.
The protocol's reliance on MEG imaging may limit initial deployment to academic centers with appropriate facilities. The manufacturer indicated it is exploring fMRI-based alternatives for broader clinical adoption.
Source
Reporting based on coverage from JAMA Otolaryngology. This article is editorial summary intended for general information; it is not medical advice.